Eric Floyd

Eric Floyd, MS, MBA, Ph.D., joined as the Senior Vice President of Regulatory Affairs and Quality Assurance in July 2020. He previously served as a consultant to the company from July 2019 to June 2020.

Dr. Floyd has more than 23 years of pharmaceutical and biotechnology experience in Regulatory Affairs roles of increasing responsibility at Merck, Aventis, Novartis, Lundbeck, Axovant Sciences, and Neurogene, Inc. Dr. Floyd has a passion for addressing the unmet medical needs of patients with few to no therapeutic options. Most recently, he served as founder and Chief Regulatory Officer at Neurogene, Inc. Neurogene is focused on developing life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases. Dr. Floyd previously served as the Global Head of Regulatory Affairs at Axovant Sciences and the US Head of Regulatory Affairs at Lundbeck, where he was responsible for strategic regulatory and clinical development activities related to the orphan drug approvals of Sabril (vigabatrin), Onfi (clobazam) and Northera (droxidopa) as well as Anti-Depression and Schizophrenia drug approvals.

Dr. Floyd serves as an adjunct faculty member in the Department of Neuroscience at Harvard Medical School and Wake Forest University School of Medicine. He also serves as a board member to Virpax Pharmaceuticals, Advent Therapeutics Inc., and is also a member of the Board of Trustees of Meharry Medical College.